Under the agreement, Cephalon will use Celator’s proprietary technology in an ongoing drug development and life-cycle management program at Cephalon.
Celator Pharma CEO Scott Jackson said they are pleased that they progress to date allows Cephalon and Celator to advance this promising work.
"It is rewarding to have a company of Cephalon’s stature demonstrate the potential of our technology in its portfolio and make the ongoing financial commitment to continue this research," Jackson said.